GlobeNewswire by notified

Saniona appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee

Share

PRESS RELEASE

16 September 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the appointment of Robert E. Hoffman to its board of directors, as resolved at the extraordinary shareholders’ meeting held on September 16, 2021. Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, and leadership.

“Robert’s depth of experience leading and advising U.S.-listed companies on corporate finance, investor relations and related activities will be valuable as we continue to develop our board and evaluate a future U.S. listing,” said J. Donald deBethizy, Chairman of the Saniona Board of Directors. 

“I see in Saniona a company with a considerable amount of untapped potential. There is incredible depth in the pipeline and the talent, and I look forward to supporting and advising the team on how to ensure Saniona’s potential is appreciated and valued,” said Hoffman.

Hoffman currently sits on three publicly-traded company boards with market capitalizations ranging from $30 million to $300 million (ASLAN Pharmaceuticals – Nasdaq: ASLN, Kintara Therapeutics – Nasdaq: KTRA, and Antibe Therapeutics – TSX: ATE), serving as chairman on one of the boards and as financial expert on the other boards. Hoffman also serves as a board member of the Association of Bioscience Financial Officers and FibroBiologics, Inc., a private biotechnology company. In his most recent operating role, Hoffman was Chief Financial Officer (CFO) of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed, commercial-stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. Hoffman’s career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he was a member of the founding management team and rose to become CFO, holding that position for ten years. While at Arena, he was involved in its Initial Public Offering (IPO) and financings, raising more than $1.5 billion. Hoffman was the financial lead in two Arena acquisitions, including a Swiss manufacturing facility, and he became managing director of the facility upon the closing of the transaction. Hoffman also was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020), advising the United States accounting rulemaking organizations on emerging issues and new financial guidance. As a founder of Day For Change, a not-for-profit that serves underprivileged and abused children in San Diego, Hoffman has served on its board of directors for 20 years. Hoffman received his BBA in accounting from St. Bonaventure University and is a licensed CPA (Inactive) in the State of California.

Hoffman is considered independent in relation to the company, its senior management and major shareholders. Hoffman does not own shares in Saniona.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 17.50 CEST on 16 September 2021.

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients suffering from rare diseases for which there are a lack of available treatment options. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 ion channel modulators, of which more than 20,000 are Saniona’s proprietary compounds. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Led by an experienced scientific and operational team, Saniona has an established research organization in the Copenhagen area, Denmark, and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Palette Life Sciences Announces Completion of $30 Million Equity Financing and Expansion of the Board of Directors20.10.2021 23:45:00 CEST | Press release

-Funds will be used for expansion of commercial US footprint and acceleration of clinical development of Barrigel®- SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, a Swedish domiciled, fully integrated global life sciences company dedicated to improving patient outcomes, announced today that the company has completed a $30 million equity financing during the spring and also expanded its Board of Directors by five members. “This capital raise allows for Palette Life Sciences’ to continue to expand our commercial presence in the United States and other key markets and bring products like Barrigel® to the global marketplace,” said Per G. Langö, Chief Executive Officer and Board Director of Palette Life Sciences. “We are excited to strengthen our team with the appointment of exceptional leaders. Each will provide significant expertise in their respective functions as we expand our product portfolio and deliver best in class care to our

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH20.10.2021 23:07:18 CEST | Press release

In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASHNATIVE was the first clinical trial demonstrating an effect on the composite histology endpoint of NASH resolution and improvement of fibrosisNATiV31, a pivotal phase III trial of lanifibranor in NASH is currently ongoing with first clinical trial sites initiated and patients screened in the United States and if topline results, expected H2 2024, are positive, intent is to seek U.S. accelerated approval and EU conditional approval Daix (France), Long Island City (New York, United States), October 20, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical

Zoom Named a Leader in 2021 Gartner® Magic Quadrant™ for Unified Communications as a Service20.10.2021 19:00:00 CEST | Press release

SAN JOSE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), today announced that analyst firm Gartner has named Zoom a Leader in the 2021 Magic Quadrant for UCaaS. This is the second time Zoom has been named in the Gartner Magic Quadrant for UCaaS (2020 was the first year that Zoom was recognized) and its second consecutive time as a Leader. The report analyzed 14 companies in the UCaaS space, naming Zoom as a Leader. “We are honored that Gartner has named Zoom a Leader in the Magic Quadrant for UCaaS for the second straight year,” said Eric S. Yuan, CEO of Zoom. “Zoom is committed to providing frictionless, reliable, and secure technology to empower modern, distributed workforces, and we believe we were recognized due to the convenience and accessibility of our UCaaS solutions, including Zoom Meetings, Zoom Chat, and Zoom Phone. We will continue to work hard to meet current and emerging communication demands and deliver happiness to all of our glo

AMG Advanced Metallurgical Group N.V. Schedule for Third Quarter 2021 Earnings Release20.10.2021 19:00:00 CEST | Press release

Amsterdam, 20October 2021 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") will release its third quarter 2021 financial results on Wednesday, October 27, 2021 at approximately 18:00 CEST. AMG will host a conference call to discuss its financial results for the third quarter 2021 at 15:00 CEST (14:00 BST / 9:00AM EDT) on Thursday, October 28, 2021. Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows: Europe +44 (0)330 027 1846 North America +1 334 777 6978 When prompted, please provide the confirmation code (7571073) and an operator will direct you onto the call. The conference call will be available on the website www.amg-nv.com within twenty-four hours following completion of the call. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacu

Kitron: Allokering av opsjoner20.10.2021 17:16:02 CEST | Pressemelding

(2021-10-20) Styret i Kitron ASA ("Selskapet" eller "Kitron") vedtok 20. oktober 2021 å utstede 1 440 000 opsjoner, hvoretter 70 000 opsjoner er re-allokert fra Subprogram A (2019-2022), 120 000 opsjoner er re-allokert fra Subprogramn B (2020-2023) og 1 250 000 er allokert fra Subprogram C (2021-2024). Etter allokeringen av opsjoner, vil det være 80 000 opsjoner under Subprogram A (2019-2022) som ikke er allokert og som kan re-allokeres i henhold til beslutning fra styret. Opsjonene blir utstedt i henhold til Kitrons langsiktige insentivprogram for 2019-2022 og styrets retningslinjer for godtgjørelse til ledende ansatte, som vedtatt av ordinær generalforsamling avholdt 21. april 2021. Aksjeopsjonsprogrammet og egenskapene til opsjonene er beskrevet i note 19 og 27 til Kitrons årsregnskap for 2020. Totalt er det allokert 1 120 000 opsjoner til primærinnsidere som følger: * CEO Peter Nilsson mottok 270 000 opsjoner fra Subprogram C. Etter tildelingen har Peter Nilsson 1 030 000 opsjoner

Kitron: Allocation of options20.10.2021 17:16:02 CEST | Press release

(2021-10-20) On 20 October 2021, the board of directors of Kitron ASA (the "Company" or "Kitron") resolved to issue 1,440,000 options, whereof 70,000 options are re-allocated from Subprogram A (2019-2022), 120,000 options are re-allocated from Subprogram B (2020-2023) and 1,250,000 options are allocated from Subprogram C (2021- 2024). Following the allocation of options, there will be 80,000 options under Subprogram A (2019-2022) which are not allocated and that may be re-allocated subject to the decision by the board of directors. The options are issued in accordance with Kitron's long term incentive program 2019-2022 and the board of directors' guidelines for remuneration of senior executives, as approved by Kitron's annual general meeting held 21 April 2021. The share option program and properties of the options are described in note 19 and 27 in Kitron's annual financial statements for 2020. A total of 1,120,000 options are allocated to primary insiders as follows: * CEO and Presid

Invitation to conference call and webcast of Sinch interim report for the third quarter of 202120.10.2021 17:00:00 CEST | Press release

Stockholm, Sweden – October 20, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, will publish its interim report for the third quarter 2021 on Tuesday, November 2, 2021, at 07:30 CET. A conference call and a webcast will take place at 14:00 CET the same day where Oscar Werner, CEO, and Roshan Saldanha, CFO, will present the report. There will be a possibility to ask questions after the presentation. Time for publication of the interim report Tuesday November 2, 2021, at 07:30 CET Time for conference call and webcast Tuesday November 2, 2021, at 14:00 CET Conference call dial-in details Please make sure that you are connected to the conference by calling in to register a few minutes before the call begins. Sweden: +46 (0) 8 506 92 180 UK: +44 (0) 2071 928 000 US: +1 631 510 7495 Access code: 698 7713# Webcast and slide deck The live webcast will be available at investors.sinch.com/webcast The presentation and report will be available at inv